Updated trial data for Pfizer-BioNTech’s bivalent COVID booster showed a “substantially higher” immune response in adults than the original vaccine, the companies said.
First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a “substantially higher” immune response in adults than the original COVID-19 vaccine.
“As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.5 sublineages,” said Pfizer Chief Executive Albert Bourla.
In another piece of good news, Pfizer and BioNTech shares were also lifted by a report in The Wall Street Journal that the Chinese government has agreed to approve the companies’ COVID-19 vaccines for foreign residents in China and has also held talks to approve those vaccines for the broader population.
According to a New York Times tracker, the daily average of new cases rose to 40,101 on Thursday from 38,208 on Wednesday, and was up 6% from 14 days ago.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccinePfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday.
Read more »
Pfizer, BioNTech start COVID-flu combination vaccine studyU.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Read more »
Pfizer, BioNTech launch combo COVID-flu vaccine studyPfizer and BioNTech aim to enroll 180 U.S. volunteers between the ages of 18 and 64 for an early-stage trial to assess the safety, efficacy and optimal dosage.
Read more »
Pfizer and BioNTech creating combined flu, COVID vaccineThe companies said that 180 U.S. adults ages 18-64 are part of the Phase 1 study. It administered the first dose of the combined vaccine this week.
Read more »
Pfizer-BioNTech testing combination flu-COVID-19 vaccineThe WHO estimates 290,000 to 650,000 people worldwide die of flu-related causes every year. About 1.1 million people in the U.S. have died from COVID-19.
Read more »
WSJ News Exclusive | General Mills, Audi and Pfizer Join Growing List of Companies Pausing Twitter AdsA growing list of brands have paused their Twitter ads since Elon Musk's takeover, including General Mills, Audi and Pfizer, people familiar with the matter say
Read more »